Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegfilgrastim vs Filgrastim in AML
NCT00114764Phase 2Completed
- Sponsor
- Amgen
- Start
- Mar 2003
- Primary completion
- Apr 2004
- Modality
- Recombinant Proteins and Enzymes
01
Overview
Phase 2, randomised, double-blind trial of pegfilgrastim in acute myeloid leukemia (AML) (2 arms), sponsored by Amgen. Primary endpoint: Time to recover from severe neutropenia. Started Mar 2003; status: completed.
02
Drugs
pegfilgrastim
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00114764.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00114764.